Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | WDR5 | P61964 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760383 | 0.93 | MAPT (0.44) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL13138459 | 0.93 | MAPT (0.44) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL5760369 | 0.93 | MAPT (0.44) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL5760364 | 0.93 | MAPT (0.44) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL7016453 | 0.92 | MAPT (0.40) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL13008041 | 0.92 | MAPT (0.43) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL7222960 | 0.91 | MAPT (0.43) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL7007033 | 0.89 | MAPT (0.47) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL7014253 | 0.89 | MAPT (0.50) | MAPTALDH1A1TSHRHTTTP53 | |
| SCHEMBL5763871 | 0.89 | MAPT (0.43) | MAPTALDH1A1TSHRHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | claimed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | claimed |
| EP-1105387-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000009498-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) | 2000-02-24 | — | — | WO | claimed |
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100113524-A1 | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | disclosed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1105387-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009498-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ABCB11, ATP6AP1, CYP4B1 | MAPT 3955/4885ALDH1A1 625/4885TSHR 1190/4885 |
| US-20100113524-A1 | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety | ABCB11, ATP6AP1, PAH | MAPT 3840/4885ALDH1A1 290/4885TSHR 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.